High-dose chemotherapy with autologous stem cell transplantation in patients with newly diagnosed multiple myeloma can prolong survival but is not curative. Maintenance therapy post transplant may prolong the diseasefree interval and impact overall survival. We have conducted a phase II pilot study of 28 post transplant myeloma patients treated with a sequential, cycling maintenance regimen. The regimen was designed to include a variety of active myeloma agents chosen for ease of administration to enhance patient compliance and scheduled sequentially to minimize toxicity. The 12-month cycling schedule included dexamethasone (months 1-3); melphalan and prednisone (months 4, 5); cyclophosphamide and prednisone (months 6, 7); a-interferon (months 8-10); followed by a drug holiday (months 11, 12). The regimen was generally well tolerated with five patients developing reversible grade III-IV toxicity (diabetes-induced hyperglycemia in four, neutropenia in one). There was one toxic death on study due to non-neutropenic pneumonia and sepsis. Median event-free survival from transplant was 36.9 months (95% CI 23.6 -upper limit not yet reached) with median overall survival not yet reached at a median follow-up of 44 months. This concept of cycling, sequential maintenance with various agents, perhaps including newer biological, targeted agents, warrants further investigation in multiple myeloma.
Introduction
The current standard of treatment for newly diagnosed, advanced-stage multiple myeloma is high-dose melphalan followed by autologous stem cell transplantation (ASCT). With this aggressive upfront approach, survival can be prolonged by approximately 1-2 years. However, even with complete response rates post transplant of 10-20%, most patients will ultimately relapse. 1 Maintenance therapy after transplantation, by reducing minimal residual disease, is theorized to prolong the plateau period of response and/or convert a partial response to a complete response. This may potentially translate into a prolongation in overall survival. This management approach, however, may also encourage drug resistance, increase side effects, and decrease quality of life. Thus, the potential benefits must be weighed against the disadvantages in controlled clinical trials.
In the present study, we assessed the toxicity, compliance, and responses rates to a novel maintenance regimen comprised of multiple agents known to be active in myeloma. These agents were given sequentially in short cycles and in lower doses than used in induction therapy to minimize the cumulative toxicity associated with continuous use of any one agent/regimen. We avoided use of agents such as vinca alkaloids, epidophyllotoxins, and anthracyclines, which are susceptible to drug resistance via the mdr phenotype and require parenteral administration. As well, by avoiding agents that cause significant cosmetic effects (i.e. alopecia), a higher rate of patient compliance could be expected. Glucocorticoids, one of the most active agents in myeloma, played a prominent role in our maintenance schema with intermittent or alternate day dosing aimed at minimizing steroid toxicity and adrenal suppression. Cumulative myelosuppression was also avoided by cycling the different drug regimens and including a 2-month drug-free interval. Results from 28 myeloma patients treated with this maintenance regimen at a median follow-up of 44 months post transplant are described.
Patients and methods

Trial design and patients
Between October 1998 and August 2000, 28 patients with multiple myeloma were registered on this study. All patients had advanced-stage disease (Salmon Durie stage II or III) for which they had undergone high-dose chemotherapy with a single autologous stem cell transplant. Standard transplant procedure for all patients was comprised of induction therapy with 3-4 cycles of VAD chemotherapy, stem cell mobilization using cyclophosphamide 2.5 g/m 2 and G-CSF 10 mg/kg daily for 9-12 days, and a transplant regimen of intravenous melphalan 200 mg/m 2 . Other key inclusion criteria for the study included age X18 years; measurable disease post transplant; evidence of adequate hematopoietic function (engraftment) with absolute neutrophil count41 Â 10 9 /l, platelets450 Â 10 9 /l and red cell transfusion-independent; and adequate performance status with ECOG o2. Patients with severe renal dysfunction (serum creatinine4300 mmol/l), recurrent infections (precluding steroid use as per the discretion of the treating physician), concurrent malignancies, or significant liver dysfunction were excluded. The protocol was approved by the Research Ethics Board for the Princess Margaret Hospital, Toronto, Ontario.
Study design
This was a phase II, nonrandomized, single-institution study. Written, informed consent was obtained from all patients prior to enrollment. Patients were registered and started the maintenance regimen within 6 months of ASCT.
Maintenance regimen A 12-month schedule of rotating drug regimens including a 2-month drug-free break was used as follows (Table 1) : Months 1, 2, and 3: oral dexamethasone 20 mg daily Â 4 days administered at the beginning of every 2-week period throughout the 3 months. Months 4 and 5: melphalan 6 mg/m 2 orally and prednisone 100 mg orally, both daily Â 4 days at the beginning of each month. Month 6, 7: cyclophosphamide 400 mg orally weekly and prednisone 50 mg orally on alternate days administered throughout the 2 months. Months 8-10: IFNa 3 Â 10 6 units subcutaneously three times weekly administered Mondays, Wednesdays, Fridays throughout the 3 months. Months 11, 12: 2 month break (off all treatment). For all grade III-IV NCIC toxicity, drug(s) were held and reassessed weekly until pgrade I, after which maintenance could resume with dose modifications. Blood counts were performed at the beginning of each cycle (month) with dose adjustments made for incomplete recovery of neutrophils and platelets. All patients with osteolytic bone disease and/or osteopenia received concurrent monthly pamidronate. Routine antibiotic prophylaxis was not used, but for patients with recurrent infections prior or during course of the study, ciprofloxacin 250 mg p.o. b.i.d. was recommended. Patients were scheduled to complete 2 years of maintenance as per study protocol. After 2 years, patients were given the option to continue maintenance off-study.
Assessments
Quantitative immunoglobulins, 24 h urine for paraprotein quantitation, complete blood count with differential, serum creatinine, serum calcium, and liver enzymes (AST, alkaline phosphatase, bilirubin, LDH) and bone marrow aspirate and biopsy were measured at 3-6 months post transplant, prior to starting maintenance therapy. Response status was documented at the initial visit. After maintenance had been initiated, patients were assessed clinically for toxicity and with the above tests (excluding bone marrow) at 2-3-month intervals to monitor disease status. Complete blood counts to assess for cytopenias due to therapy were performed at minimum once monthly during the treatment months. A complete skeletal survey was obtained on a yearly basis. Bone marrow aspirates and biopsies were performed as needed for plasma cell quantitation to confirm complete remission (CR) status. A myeloma-specific quality of life questionnaire was completed by patients every 3 months. 2 Response criteria CR was defined as the disappearance of all soft tissue lesions, the absence of serum and urinary M components (on both electrophoresis and immunofixation studies), and bone marrow plasmacytosis p3%. A partial remission (PR) was defined as 450% reduction in the M component in serum or 475% reduction in urinary paraprotein (compared to baseline). A very good partial response (VGPR) was defined as the disappearance of all soft tissue lesions, bone marrow plasmacytosis p10%, but residual trivial serum and urinary M components. Stable disease (SD) was defined as o50% reduction in serum or urinary paraprotein. Progressive disease (PD) was defined by a reappearance of serum or urine paraprotein in complete responders, the development of new lytic lesions, or a 425% increase of the M protein (serum or urine) above the lowest level recorded at any time after transplant.
Statistical analysis
Descriptive statistics were performed using SAS software. Responses to maintenance therapy were compared to disease status noted at the initial post transplant visit. Event-free survival and overall survival were determined from the day of transplant and from the day of Events were defined as myeloma relapse or progression, treatment-related toxic deaths, and deaths from all other causes.
Results
Patient characteristics
Patient characteristics are listed in Table 2 . There were 17 male and 11 female subjects with a median age at transplant of 54 years (range 40-65 years). The median interval from diagnosis to transplant was 11.4 months (range 5. A total of 14 of these progressing patients were concurrently on active maintenance therapy. In all, 14 patients had completed 2 years of maintenance but had chosen to continue maintenance off-study. Of these, six went on to progress between 26 and 37 months post transplant.
In total, 11 patients (39%) have died. Causes of death were due to progressive disease (10 patients) and pneumonia (one patient). Median event-free survival was 36.9 months (95% CI 23.6 -upper limit not yet reached) with a 3-year EFS of 53.6% (95% CI 38.0-75.6) (Figure 1 ). Median overall survival has not yet been reached, but 3 year OS was 75% (95% CI 60.6-92.9) (Figure 2 ).
Toxicity
Toxicities were generally mild and tolerable (NCIC grade II or less) (Table 3) . Fatigue, flu-like symptoms, insomnia, and sexual dysfunction (mostly low sexual drive) were common complaints, occurring primarily during administration of IFNa. In two patients, IFNa was discontinued at patient request (due to toxicities such as fatigue, flu-like symptoms), but maintenance otherwise continued. In one patient, IFNa was dose-reduced for grade III neutropenia. Steroid-induced diabetes mandated use of hypoglycemic Time from transplant (months) % Probability agents in four patients and steroid dose reductions were required for mood swings in two patients. Only one patient actually required discontinuation of steroid (refractory hypertension). Infections that were common while on maintenance: bronchitis (three), localized herpes zoster (three), pneumonia (three), conjunctivitis (two), and infectious diarrhea (one). Infections were mild and treated as outpatients except for one patient who developed a severe pneumonia during his 6th month of maintenance. He required intensive care with ventilatory support and subsequently died of sepsis. This patient had a 13-year history of stable pulmonary fibrosis. Hematologic toxicity was infrequent. As discussed above, one patient developed an asymptomatic grade III neutropenia on IFNa which resolved with one dose reduction. One patient developed a transient mild thrombocytopenia (platelet nadir 115 Â 10 9 /l) while on IFNa. No significant hematologic toxicities during any of the other months were noted. No patients have developed myelodysplasia or secondary leukemia to date.
Patient compliance
Overall, 71% (20/28 patients) remained on study for 1 year and 50% (14/28 patients) completed the planned 2 years of maintenance. Causes for study discontinuation within the first 2 years were progressive disease (eight), toxicity (four), and patient preference (two). Infections accounted for most discontinuations due to toxicity. A total of 14 patients who completed the 2 years of maintenance chose to continue the regimen off-study (duration on study for all patients, range 2.8-48 months). After 2 years, the majority of study withdrawals were due to progressive disease (six) or patient/physician preference (five).
Quality of life
Quality of life (QOL) data were collected from patients at 3-month intervals until the study regimen was discontinued or at patient request. The myeloma-specific QOL questionnaire was comprised of six function scales (physical, role, cognitive, emotional, social, global quality of life) and nine symptom scales/items (fatigue, pain, nausea and vomiting, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact). Details of the score calculations are published elsewhere. 2 Mean scores for each scale using a paired-test method are presented in Table 4 . In the function scales, higher scores represent higher levels of functioning. All scale scores remained stable from baseline (study entry), 6 months, and 12 months on maintenance. Without maintenance therapy, QOL scores post transplant generally improve steadily in the first year, reaching a plateau by month 12. 4 The stable QOL scores reported from our study suggest that at least for the short term, QOL improvements were likely impeded by the maintenance regimen. Insufficient data after 12 months on maintenance precluded QOL analysis beyond this period. There was a positive but not statistically significant trend toward improvements in physical function (e.g. ability to walk, perform activities of daily living, carry heavy items) and role function (e.g. ability to function at work or household jobs) over the course of the first year on maintenance as would be expected without maintenance.
Discussion
Athough maintenance therapies are frequently used in post transplant myeloma, the efficacy of this approach remains unproven. In this study, we confirm the feasibility of using a novel schedule of sequential, cycling agents/regimens known to be active in myeloma. The shortened and dosemodified cycles were, in general, well tolerated and no significant cumulative toxicities were noted. Continous use of alkylator-based oral regimens as maintenance (identical in dose and schedule to that used for induction regimens) has been used in early studies. Belch et al.
5 randomized responding patients who had entered a plateau phase from melphalan and prednisone (MP) to maintenance MP or no maintenance. Time to first relapse was significantly shorter in the no maintenance group (P ¼ 0.0011). Peest et al. 6 reported similarly significant prolongations in time to relapse/progression using a maintenance regimen of either MP or VCMP (vincristine, cyclophosphamide, melphalan, prednisone). Neither of these studies, however, was able to demonstrate an overall survival benefit over the no-maintenance control group. In addition, concerns regarding leukemogeneicity of longterm alkylator use further discouraged adoption of continuous alkylator-based therapy as maintenance. 7, 8 In our study, at a median follow-up of 44 months, we have reported no cases of secondary leukemia or myelodysplasia. Although patient numbers are small (n ¼ 28), one could speculate that the cycling, noncontinous use of alkylators as used in our study has less propensity to leukemogenicity. Longer follow-up is clearly warranted for confirmation.
The most common maintenance regimen used to date in the post transplant myeloma setting is single agent alphainterferon (IFNa) using doses of 3-5 mU/m 2 s.c. three times weekly. Cunningham et al. 9 published the only randomized trial of IFNa maintenance following high-dose therapy and ASCT. PFS and OS were highly favorable for the IFNa arm at 52 months follow-up when compared to no maintenance. In contrast, a large intergroup study comparing high-dose to standard-dose therapy with responders in both groups randomized to IFNa or no maintenance reported no benefit from IFNa maintenance. 10 More substantial data exist for the use of IFNa as maintenance following conservative chemotherapy (no ASCT). However, the effect on survival in this population is modest (median survival increased by approximately 4 months).
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Although the Cunningham study reported reasonable toxicity with continuous IFNa use (only 4/42 patients discontinued pIFN due to side effects; 9/42 required dose modifications), other nonrandomized studies in the post transplant setting report poor patient compliance due to systemic or hematologic side effects. 1, [12] [13] [14] [15] [16] High drop-out rates using continuous dosing of IFNa clearly limit its utility for long-term maintenance. In our study, we found that when used intermittently and restricted to only 3 months of continuous use per year, IFNa was well tolerated with high patient compliance. Significant hematologic toxicity was not seen.
Steroids alone (usually high-dose dexamethasone pulsed over several days per month or alternate-day prednisone) have been used for myeloma maintenance. 17, 18 In a Southwest Oncology Group (SWOG) study, 50 mg alternate-day oral prednisone was superior over 10 mg alternate-day prednisone with prolongations in PFS (14 versus 5 months; P ¼ 0.003) and OS (37 versus 26 months; P ¼ 0.05). 18 Patients in this trial were restricted to those responding to a VAD-like induction regimen. In a Canadian NCIC trial, oral dexamethasone pulsed monthly (40 mg daily Â 4 days) following mephalan-based standard therapy led to superior PFS, but not OS, over no maintenance. 19 Although these results are supportive of the use of steroid maintenance following conservative chemotherapy, this cannot clearly be generalized to the post transplant setting. In our study, we incorporated dexamethasone alone and alternate-day prednisone into our maintenance therapy.
Other agents/regimens such as IFNa combinations, 17, 20, 21 PAIV (prednisone, doxorubicin, azathioprine, vincristine), 22 levamisole, 23 and more recently thalidomide 24 have been studied or are currently under study for use as myeloma maintenance post transplant. To date, however, no particular agent or regimen emerges superior. Our maintenance regimen is unique in using a sequential, cycling schedule providing exposure to multiple agents active in myeloma. Cumulative toxicities that occur with continuous, long-term use of one agent or concurrent use of multiple agents may be minimized. Furthermore, it is convenient, easy to administer for both patient and healthcare provider, and does not appear to cause any deterioration in QOL. Using this novel maintenance regimen, the median times to progression/relapse from transplant appear comparable to results from other post transplant studies using IFNa alone. 1, 25, 26 However, definitive conclusions from this small phase II study are not possible. Nevertheless, we have demonstrated the feasibility of applying this conceptual approach to maintenance therapy in myeloma and suggest that novel drugs such as thalidomide, IMiDs, or bortezomib used in a sequential, cycling maintenance schedule may be promising for future investigation.
